ImmunityBio Expands Globally, Driving 266% Share Price Increase in 2026

ImmunityBio (IBRX) has experienced a 266% increase in its share price year-to-date, driven by its global expansion plans and strong performance of its bladder cancer treatment, Anktiva. The company reported a 671% increase in 2025 revenues to $113 million, with sales volume rising 750%.

By Angelica Ballesteros Fri, April 17, 2026 at 2:26 PM GMT+3 2 min read · Yahoo Finance · April 17, 2026, 11:26 UTC

ImmunityBio Expands Globally, Driving 266% Share Price Increase in 2026

Tickers: $IBRX

Topics: Anktiva treatment funding raise global expansion regulatory approval stock price increase

Read the full article at Yahoo Finance

More World news

Moderna Shares Decline Following Analyst Day Projections and Future Cost Concerns Motley Fool · November 12, 2026, 17:13 UTC
United Airlines Restricts AI Agent Access to Booking Systems Due to Cybersecurity and Regulatory Concerns TechCrunch · November 12, 2026, 17:17 UTC
Global Payments Shares Drop 12% Following Reports Private Equity Firms Abandoned Takeover Bid Seeking Alpha · November 12, 2026, 17:14 UTC
Nvidia Appoints Colette Kress as Interim CEO Following Jensen Huang's Resignation CNBC · November 12, 2026, 16:59 UTC
Brookfield Corporation Reports Strong Third Quarter Earnings Growth and Increased Share Buybacks Motley Fool · November 12, 2026, 17:08 UTC
Franco-Nevada Reports Q3 2026 Revenue Growth Driven by Higher Gold and Oil Prices Motley Fool · November 12, 2026, 17:10 UTC
Stratasys Reports Q3 2026 Revenue Growth Driven by Aerospace and Defense Demand Motley Fool · November 12, 2026, 17:11 UTC
Jim Cramer Advises Profit-Taking Following Jensen Huang's Resignation at Nvidia CNBC · November 12, 2026, 16:59 UTC
LexisNexis Report Shows Elevated U.S. Auto Insurance Shopping Volumes in Q3 2026 PR Newswire · November 12, 2026, 17:12 UTC
Suburban Propane Partners Outlines $60M-$70M Capital Expenditures for Fiscal 2027 Seeking Alpha · November 12, 2026, 17:00 UTC